AMAG : Analysis & Opinions

  1. Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst ...

    January 23, 2015
    Minerva Neurosciences, Inc. announced encouraging preliminary results from a phase I study on its sleep disorder candidate, ...
  2. Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst ...

    January 22, 2015
    Endo International has priced $1.2 billion aggregate principal amount of 6.00% senior notes due Feb 2025 at par with a face ...
  3. Bayer Announces Updates to European Label of Xarelto - Analyst ...

    January 21, 2015
    Bayer (BAYRY) announced that the label for its anticoagulant drug Xarelto will now include specific guidance for doctors ...
  4. Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst ...

    January 21, 2015
    Bristol-Myers Squibb Company announced certain leadership changes approved by its board of directors including the appointment ...
  5. Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst ...

    January 21, 2015
    Hospira, Inc. (HSP) announced that it has received 510(k) regulatory clearance for the Plum 360 infusion system with Hospira ...
  6. Actavis/Gedeon Richter Present Schizophrenia Drug Data - Analyst ...

    January 20, 2015
    Actavis and partner Gedeon Richter announced encouraging data from a phase III study on cariprazine.
  7. Celgene Up as Otezla Gains EU Approval for Two Indications - ...

    January 19, 2015
    Celgene Corporation announced that the European Commission has granted approval to Otezla for two therapeutic indications.
  8. Amgen (AMGN) Reveals Mixed Results from Vectibix Studies - Analyst ...

    January 16, 2015
    Amgen (AMGN) announced new data from the phase II PEAK study and the phase III PRIME study on Vectibix.
  9. Illumina Unveils 3 NGS Systems, Modifies Business Strategy - ...

    January 16, 2015
    llumina's (ILMN) NextSeq 550 System is the first next generation sequencer that allows array scanning.
  10. Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - ...

    January 15, 2015
    Sarepta Therapeutics Inc. (SRPT) announced that it has initiated dosing its first patient in a phase I/II study on SRP-4 ...
  11. Illumina Declares Impressive Q4, 2014 Preliminary Results - Analyst ...

    January 15, 2015
    Illumina (ILMN) estimates total revenue of $512 million for the yet to-be-reported fourth quarter, which reflects a massive ...
  12. Regado Biosciences to Merge with Tobira Therapeutics - Analyst ...

    January 15, 2015
    Regado Biosciences announced that it has entered into a definitive merger agreement with privately-held Tobira Therapeutics, ...
  13. Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst ...

    January 15, 2015
    Vical announced that it has entered into an agreement with a Japanese biopharmaceutical company, AnGes MG.
  14. AstraZeneca Announces Encouraging Data from Brilinta Study - ...

    January 15, 2015
    AstraZeneca (AZN) announced encouraging top-line results from the PEGASUS-TIMI 54 study on Brilinta.
  15. BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst ...

    January 14, 2015
    BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II ...
  16. Amgen Maintains 2015 View, Expects Several Drug Launches - Analyst ...

    January 14, 2015
    Amgen (AMGN) said that it is maintaining its 2015 revenue guidance.
  17. Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal ...

    January 14, 2015
    Qiagen (QGEN) expects this buyout to provide approximately $20 million CER (constant exchange rates) of incremental net sales
  18. Celgene's Preliminary Results & 2015 Outlook Encouraging - Analyst ...

    January 13, 2015
    Celgene Corporation (CELG) provided encouraging guidance for 2015.
  19. Pharmacyclics Reports Preliminary Results and 2015 Outlook - ...

    January 13, 2015
    Pharmacyclics, Inc. (PCYC) provided preliminary 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook ...
  20. Will Qiagen's Qiasymphony Placements Weave Magic in 2015? - Analyst ...

    January 13, 2015
    Qiagen's (QGEN) QIAsymphony automation solution refers to a revolutionizing molecular testing workflow which offers flexible ...
  21. Agenus Soars on Immuno-Oncology Agreement with Incyte - Analyst ...

    January 12, 2015
    Agenus (AGEN) inked a global license, development and commercialization agreement with Incyte Corporation for the development ...
  22. Conatus Announced Results from Emricasan Studies - Analyst Blog

    January 12, 2015
    Conatus (CNAT) announced top-line results from studies on emricasan in organ-impaired patients.
  23. AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst ...

    January 12, 2015
    AMAG Pharmaceuticals (AMAG) provided preliminary results for the fourth quarter and full year 2014 as well as its 2015 financial ...
  24. Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - ...

    January 12, 2015
    Vertex Pharmaceuticals (VRTX) provided an update on its cystic fibrosis pipeline and issued preliminary financial guidance ...
  25. Qiagen (QGEN) Launches Next-Gen TB Infection Test - Analyst Blog

    January 12, 2015
    Qiagen's (QGEN) QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection.
  26. Affymetrix (AFFX) Expands Genotyping Arrays Product Line - Analyst ...

    January 12, 2015
    Provider of life science tools and molecular diagnostic products, Affymetrix, Inc. (AFFX), is expected to highlight various ...
  27. Bristol-Myers Opdivo Study Stopped on Favorable Data - Analyst ...

    January 12, 2015
    Bristol-Myers Squibb Company (BMY) announced that a phase III study on Opdivo, was stopped early because the independent ...
  28. Biogen Reveals Positive Data from Acute Optic Neuritis Study ...

    January 9, 2015
    Biogen Idec (BIIB) announced positive top-line results from a phase II study on anti-LINGO-1 for the treatment of patients ...
  29. AbbVie 2015 Earnings Guidance Projects Strong Y/Y Growth - Analyst ...

    January 9, 2015
    AbbVie (ABBV) announced that it expects earnings in the range of $4.25 to $4.45 per share for 2015.
  30. Arena Pharmaceuticals Soars on Positive Study Results - Analyst ...

    January 8, 2015
    Arena Pharmaceuticals' (ARNA) shares skyrocketed after announcing encouraging results from a phase Ib study on APD334.
  31. Alkermes Soars on Positive Schizophrenia Drug Results - Analyst ...

    January 8, 2015
    Alkermes (ALKS) reported positive top-line data from a mid-stage study on its experimental schizophrenia treatment, ALKS ...
  32. Eli Lilly Maintains '14 View, Growth to Resume in 2015 - Analyst ...

    January 8, 2015
    Eli Lilly (LLY) provided an overview of its plans to enhance revenue and expand margins. It also issued the financial guidance ...
  33. Alkermes Gains on Positive Depression Drug Study Data - Analyst ...

    January 7, 2015
    Alkermes (ALKS) reported positive top-line results from the FORWARD-1 study on its major depressive disorder candidate, ALKS ...
  34. CytRx Jumps on Positive Results from Brain Cancer Study - Analyst ...

    January 7, 2015
    CytRx Corporation (CYTR) jumped 15.8% after announcing encouraging interim results from a phase II study on aldoxorubicin.
  35. Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up - Analyst ...

    January 6, 2015
    Amgen Inc. (AMGN) and Kite Pharma (KITE) are tying up for the development and commercialization of chimeric antigen receptor ...
  36. Salix CEO to Step Down, Inventory Issues Remain in Focus - Analyst ...

    January 6, 2015
    Salix Pharmaceuticals' (SLXP) President and CEO, Carolyn Logan, has decided to step down from its position by the end of ...
  37. Aquinox Starts Dosing for an Atopic Dermatitis Study - Analyst ...

    January 5, 2015
    Aquinox (AQXP) has started dosing in the phase II KINSHIP study on its atopic dermatitis candidate, AQX-1125.
  38. Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst ...

    January 5, 2015
    On Jan 3, Zacks Investment Research upgraded Amgen (AMGN) to a Zacks Rank #1 (Strong Buy).
  39. Tekmira Jumped Following Update on its Oncology Candidate - Analyst ...

    January 2, 2015
    Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
  40. Hospira's Dyloject Cleared in the U.S. for Pain Management - ...

    December 31, 2014
    The FDA has approved Hospira's (HSP) proprietary nonsteroidal anti-inflammatory drug analgesic, Dyloject.
  41. AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog

    December 30, 2014
    AMAG Pharmaceuticals (AMAG) and Takeda (TKPYY) mutually terminate their licensing deal for Ferahame in the ex-U.S. territories ...
  42. Athersys Finishes Enrollment for MultiStem Cell Therapy Trial ...

    December 30, 2014
    Athersys (ATHX) announced the completion of patient enrolment process for a phase II study on its MultiStem cell therapy.
  43. Repros Gains on Positive Updates on the Status of Androxal - ...

    December 30, 2014
    Repros Therapeutics (RPRX) announced the submission of a complete response to the guidance regarding the expected NDA submission ...
  44. This Week's Activist Filings

    January 12, 2011
    Valuations are getting ahead of themselves, so it was a light week for 13D activist filings.
Trading Center